Patented Medicine Prices Review Board

The Patented Medicine Prices Review Board (PMPRB) protects and informs Canadian consumers by reviewing the prices of patented medicines sold in Canada, and by reporting on pharmaceutical trends.

We are an independent quasi-judicial body that is part of the Health portfolio, and operate at arm’s-length from the Minister of Health.

Department name

Follow:

We are in the process of moving our services and information to Ca-ciconline.com.

Our current Patented Medicine Prices Review Board website will remain available until the move to Ca-ciconline.com is complete.

Latest news

Scoping paper for the consultations on the Board's Guidelines

Scoping paper for the consultations on the Board's Guidelines

Read the Scoping Paper and review the feedback that will help inform the development of the PMPRB Guidelines.

CompassRx, 9th Edition

CompassRx, 9th Edition

This edition of the report focuses on the 2021/22 fiscal year, with a retrospective look at recent trends.

What we are doing

Corporate information

Management

Thomas J. Digby
Chairperson

Management

Vacant
Executive Director

Features

Regulatory Process

The PMPRB is responsible for ensuring the prices that patentees charge for prescription and non-prescription patented medicines sold in Canada to wholesalers, hospitals, pharmacies or others, for human and veterinary use, are not excessive.

NPDUIS Analytical Studies

Every report and publication published by the NPDUIS group.

Consultations

Consultations

Effective and meaningful stakeholder involvement is essential to enable the PMPRB to fulfil its mandate, deliver programs, launch new initiatives, and build public trust.

Page details

Date modified: